Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.302 EUR | 0.00% | +5.00% | -4.96% |
Jun. 03 | Transgene: first patient in phase II study | CF |
Apr. 10 | Transgene: presents vaccine results at AACR | CF |
Sales 2024 * | 39.2M 42.14M | Sales 2025 * | 49.2M 52.89M | Capitalization | 132M 141M |
---|---|---|---|---|---|
Net income 2024 * | -14M -15.05M | Net income 2025 * | -21M -22.58M | EV / Sales 2024 * | 3.87 x |
Net Debt 2024 * | 20.2M 21.72M | Net Debt 2025 * | 42.1M 45.26M | EV / Sales 2025 * | 3.53 x |
P/E ratio 2024 * |
-8.68
x | P/E ratio 2025 * |
-5.92
x | Employees | 141 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 34.69% |
Latest transcript on Transgene
1 week | +5.00% | ||
Current month | +5.00% | ||
1 month | -3.27% | ||
3 months | +11.47% | ||
6 months | -8.82% | ||
Current year | -4.96% |
Managers | Title | Age | Since |
---|---|---|---|
Alessandro Riva
CEO | Chief Executive Officer | 63 | 22-03-30 |
Lucie Larguier
DFI | Director of Finance/CFO | - | 16-03-31 |
Maud Brandely
CTO | Chief Tech/Sci/R&D Officer | 70 | 16-03-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 74 | 13-06-18 | |
Alain Mérieux
BRD | Director/Board Member | 85 | 90-12-31 |
Director/Board Member | 63 | 04-12-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 1.302 | 0.00% | 10,617 |
24-06-06 | 1.302 | +0.15% | 10,244 |
24-06-05 | 1.3 | 0.00% | 29,887 |
24-06-04 | 1.3 | -0.46% | 36,710 |
24-06-03 | 1.306 | +5.32% | 87,126 |
Real-time Euronext Paris, June 07, 2024 at 11:18 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.96% | 142M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- TNG Stock